AIDS 2012 Recap: Complera Switch Study
In the SPIRIT study, reported at the 19th International AIDS Conference at the end of July, switching from a protease inhibitor–based HIV treatment regimen to Complera was not only safe but also helped reduce levels of lipids—fats in the blood—and lowered heart disease risk. See the study results for yourself over at HIVandHepatitis.com.
By Liz Highleyman
People who switched to the all-in-one Complera (rilpivirine/tenofovir/emtricitabine) combination pill from a boosted protease inhibitor continued to have undetectable viral load and on average had improved lipid profiles associated with lower cardiovascular risk, according to study findings presented at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC….